Pharvaris is a clinical-stage company focused on bringing an oral bradykinin B2 receptor antagonist to patients. By targeting this clinically proven therapeutic target with novel small molecules, we are progressing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE) and other B2 receptor-mediated indications. PHA121, Pharvaris’ lead drug candidate, is a novel and potent small-molecule bradykinin B2 receptor antagonist currently under Phase 1 clinical study.

The co-founders of Pharvaris include an inventor of icatibant and the leadership from Jerini AG that developed icatibant for the treatment of HAE, now sold by Takeda under the brand name Firazyr®.